📢 Publish Your Research for Free - Full APC Waiver, No Hidden Charges. Submit Your Article Today! Submit Now →

Editor Profile

editor profile image is not found.

Dr. Vittorio Di Maso, M.D., Ph.D.

Director

Present

Azienda Ospedaliero Universitaria “Ospedali Riuniti di Trieste”

Trieste

Italy

editor profile QR Code is not found.

Dr. Vittorio Di Maso is Director of the Department of Nephrology and Dialysis at AOUTS “Ospedali Riuniti di Trieste”, Italy, where he leads a comprehensive service including acute and chronic dialysis, nephrology inpatient care, day hospital and day service activities, and specialized outpatient clinics. His clinical expertise covers a wide range of areas such as glomerular and rare kidney diseases, renal complications in pregnancy, immuno-mediated disorders, and interventional nephrology procedures, including vascular access creation, peritoneal dialysis catheter placement, and renal biopsy.

He obtained his medical degree from the University of Trieste, where he also completed his PhD in Molecular Medicine and his specialization in Nephrology. During his doctoral training, he developed advanced expertise in molecular and cellular biology applied to hepatology and nephrology. He further expanded his international experience as a recipient of the prestigious Sheila Sherlock Short-Term Fellowship, awarded by the European Association for the Study of the Liver (EASL), at the University of Geneva.

Dr. Di Maso is actively engaged in both clinical research and translational medicine. He serves as Principal Investigator in several international multicentre clinical studies, including the BEYOND phase III trial in IgA nephropathy, the VAVASC trial on vascular access classification, and studies on renal amyloidosis and chronic kidney disease-associated pruritus. His research has resulted in a large number of publications in leading journals, such as Haematologica, European Journal of Internal Medicine, Clinical Kidney Journal, Scientific Reports, and Nephrology Dialysis Transplantation. He has also contributed extensively to the Italian nephrology literature, with a focus on glomerular diseases, dialysis outcomes, vascular access, and nephrology in special populations.

In addition to his clinical and research activities, Dr Di Maso plays an important role in medical education. He is a lecturer in Nephrology at the University of Trieste, teaching across the School of Medicine, the Nursing degree programme, and various postgraduate Specialisation Schools, where he is recognised as an expert of high qualification.

He is an active member of several national and international societies, including the Italian Society of Nephrology (SIN), the European Renal Association (ERA) and has served as a board member of the Triveneto section of SIN.

  • Progressive glomerular disease: IgA nephropathy (prediction tools, therapy responses)
  • Light-chain (AL) amyloidosis: renal histopathological scoring, prognosis, renal survival
  • Vascular access in hemodialysis: AVAS classification, ultrasound mapping, optimizing creation and outcomes of arteriovenous fistulas/grafts
  • Chronic kidney disease (CKD): early detection, albuminuria (urine albumin-to-creatinine ratio), referral pathways, risk stratification
  • Kidney involvement in haematological malignancies: mechanisms, timing and impact of nephrological referral, outcomes
  • Rare glomerulopathies and secondary nephrotic syndromes: membranous nephropathy secondary to infections, C3 glomerulopathy, steroid-resistant nephrotic syndrome
  • Renal complications in systemic conditions and acute settings: acute kidney injury in sepsis, effects of hemoadsorption, kidney injury in the context of infections including COVID-19
  • Optimizing urine albumin-to-creatinine ratio testing and referral pathways for chronic kidney disease: a nominal group technique consensus study among Italian experts. Capelli I, De Benedictis M, Di Lenarda A, Di Maso V, Fabbrini P, Galli P, Garofalo C, Leone AM, aiorino MI, Marengo M, Pasqualetti S, Pesce F, Polimeni A, Provenzano M, Ribichini D. J Nephrol. 2025 Aug 20. doi: 10.1007/s40620-025-02371-w. Online ahead of print.
  • Incidence and prevalence of systemic lupus erythematosus across Italian referral centers and its clinical burden in terms of disease severity, treatment and hospitalization: The ESCULAPIO study. Mattioli I, Gasparotto M, Bergamini A, Bortoluzzi A, Ciccia F, Conti F, D'agostino MA, Fredi M, Giacomelli R, Iannone F, Mormile I, Piga M, Quartuccio L, Sebastiani GD, Tani C, Vacca A, Zen M, Bettiol A, Emmi G; ESCULAPIO consortium. Eur J Intern Med. 2025 Jun 28:S0953-6205(25)00255-9. doi: 10.1016/j.ejim.2025.06.016. Online ahead of print.
  • Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis. Rauf MU, Law S, Santostefano M, Hawkins PN, Petrie A, Cappelli F, Perfetto F, Razvi Y, Porcari A, Ravichandran S, Ioannou A, Bomsztyk J, Argirò A, Gaudio C, Antonioli E, Barilaro A, Delsante M, Di Maso V, Chiappini MG, Ogunbiyi O, Cohen OC, Martinez-Naharro A, Whelan C, Lachmann HJ, Wechalekar AD, Alberici F, Fontana M, Allinovi M, Gillmore JD. Haematologica. 2025 Jun 26. doi: 10.3324/haematol.2025.287703. Online ahead of print.
  • Real-World Outcomes of Hemoadsorption with CytoSorb® in Patients with Septic Shock: Insights from a Single-Center Study. Berlot G, Carocci P, Votrico V, Iacoviello B, Taverna N, Gerini U, di Maso V, Tomasini A. J Intensive Care Med. 2025 Sep;40(9):993-1000. doi: 10.1177/08850666251331905. Epub 2025 Apr 1.
  • Machine learning validation of the AVAS classification compared to ultrasound mapping in a multicentre study. Lawrie K, Waldauf P, Balaz P, Bortel R, Lacerda R, Aitken E, Letachowicz K, D'Oria M, Di Maso V, Stasko P, Gomes A, Fontainhas J, Pekar M, Srdelic A; VAVASC Study Group; O'Neill S. Sci Rep. 2025 Jan 20;15(1):2538. doi: 10.1038/s41598-025-86456-3.
  • Validation of arteriovenous access stage (AVAS) classification: a prospective, international multicentre study. Lawrie K, Waldauf P, Balaz P, Lacerda R, Aitken E, Letachowicz K, D'Oria M, Di Maso V, Stasko P, Gomes A, Fontainhas J, Pekar M, Srdelic A; VAVASC Study Group; O'Neill S. Clin Kidney J. 2024 Aug 30;17(9):sfae272. doi: 10.1093/ckj/sfae272. eCollection 2024 Sep.
  • [COVID-19 and Lupus Nephritis Flares in Unvaccinated Patients: A Case Report and Literature Review]. Perencin B, Zacchi A, Zanconati F, Tomietto P, Bianco F, Di Maso V. G Ital Nefrol. 2024 Jun 28;41(3):2024-vol3. doi: 10.69097/41-03-2024-07. PMID: 38943328 Review. Italian.
  • Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatment. Di Cecco C, Monticelli J, Di Bella S, Di Maso V, Luzzati R. J Chemother. 2024 Feb;36(1):31-34. doi: 10.1080/1120009X.2023.2247205. Epub 2023 Aug 21.
  • Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy. Balestra E, Barbi E, Ceconi V, Di Maso V, Conversano E, Pennesi M. Pediatr Nephrol. 2024 Jan;39(1):309-314. doi: 10.1007/s00467-023-06088-5. Epub 2023 Jul 26.
  • A urokinase-associated outbreak of Ralstonia mannitolilytica bloodstream infections in haemodialysis patients in north-eastern Italy, January to April 2023. Fabricci M, Trinca A, Talotti L, Busetti M, Fotakis EA, Merakou C, Koncan R, Ghiotti A, Negri C, Di Maso V, Bosco M, Antonelli A, Coppi M, Rossolini GM, Giuliani C, Scarpis E, Gregoretti B, Licastro D, Luzzati R, Costantino V; multidisciplinary working group; Multidisciplinary working group. Euro Surveill. 2023 Jul;28(28):2300328. doi: 10.2807/1560-7917.ES.2023.28.28.2300328.
  • Effects of the timing and intensity of treatment on septic shock patients treated with CytoSorb®: Clinical experience. Berlot G, Samola V, Barbaresco I, Tomasini A, di Maso V, Bianco F, Gerini U. Int J Artif Organs. 2022 Mar;45(3):249-253. doi: 10.1177/03913988211073812. Epub 2022 Jan 25.
  • [Droghe d'abuso e rene]. Boscutti G, Di Maso V, Marega A, Gerini U, Zacchi A, Bianco F. G Ital Nefrol. 2021 Sep 7;38(Suppl 77):2021-S77.
  • The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report. Berlot G, Tomasini A, Roman Pognuz E, Randino A, Chiella F, La Fata C, Piva M, Amato P, di Maso V, Bianco F, Gerini U, Tomietto P, Trenti T. Nephron. 2020;144(9):459-462. doi: 10.1159/000509738. Epub 2020 Jul 21.
  • Coupled Plasma Filtration Adsorption for Treatment of Capillary Leak Syndrome Superimposed to Acute Generalized Exanthematous Pustolosis: A Case Report. Di Maso V, Cozzi M, Gerini U, Bedina E, Olivo E, Bianco F, Signoretto D, Berlot G, Boscutti G. Blood Purif. 2020;49(3):372-378. doi: 10.1159/000503770. Epub 2020 Feb 18.
  • [EBV-ASSOCIATED PNEUMONIA IN PATIENT WITH GRANULOMATOSIS WITH POLYANGIITIS (GPA) IN IMMUNOSOPPRESSIVE THERAPY TREATED WITH ACICLOVIR]. Mongera N, Di Maso V, Ermacora E, Carraro M, Bregant C, Pian M, Savi U, Lorenzon E, Boscutti G. G Ital Nefrol. 2018 May;35(3):2018-vol3.
  • Transcriptional Up-Regulation of APE1/Ref-1 in Hepatic Tumor: Role in Hepatocytes Resistance to Oxidative Stress and Apoptosis. Di Maso V, Mediavilla MG, Vascotto C, Lupo F, Baccarani U, Avellini C, Tell G, Tiribelli C, Crocè LS. PLoS One. 2015 Dec 1;10(12):e0143289. doi: 10.1371/journal.pone.0143289. eCollection 2015.
  • Warfarin-related nephropathy: possible role for the warfarin pharmacogenetic profile. Di Maso V, Carraro M, Bevilacqua E, Bucconi S, Artero ML, Boscutti G. Clin Kidney J. 2014 Dec;7(6):605-8. doi: 10.1093/ckj/sfu112. Epub 2014 Oct 28. PMID: 25859382 Free PMC article.
  • Small molecule membrane transporters in the mammalian podocyte: a pathogenic and therapeutic target. Zennaro C, Artero M, Di Maso V, Carraro M. Int J Mol Sci. 2014 Nov 18;15(11):21366-80. doi: 10.3390/ijms151121366.
  • Podocyte expression of membrane transporters involved in puromycin aminonucleoside-mediated injury. Zennaro C, Rastaldi MP, Pascolo L, Stebel M, Trevisan E, Artero M, Tiribelli C, Di Maso V, Carraro M. PLoS One. 2013 Jun 20;8(6):e66159. doi: 10.1371/journal.pone.0066159. Print 2013.
  • Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Spano D, Russo R, Di Maso V, Rosso N, Terracciano LM, Roncalli M, Tornillo L, Capasso M, Tiribelli C, Iolascon A. Mol Med. 2010 Mar;16(3-4):102-15. doi: 10.2119/molmed.2009.00119. Epub 2009 Dec 21.
  • Differential proteomic analysis of subfractioned human hepatocellular carcinoma tissues. Codarin E, Renzone G, Poz A, Avellini C, Baccarani U, Lupo F, di Maso V, Crocè SL, Tiribelli C, Arena S, Quadrifoglio F, Scaloni A, Tell G. J Proteome Res. 2009 May;8(5):2273-84. doi: 10.1021/pr8009275.
  • Modern strategies to identify new molecular targets for the treatment of liver diseases: The promising role of Proteomics and Redox Proteomics investigations. Scaloni A, Codarin E, Di Maso V, Arena S, Renzone G, Tiribelli C, Quadrifoglio F, Tell G. Proteomics Clin Appl. 2009 Feb;3(2):242-62. doi: 10.1002/prca.200800169.
  • Is there an effective therapy available for non-alcoholic fatty liver disease? Di Maso V, Bellentani S. F1000 Med Rep. 2009 Jun 29;1:50. doi: 10.3410/M1-50.
  • Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Di Maso V, Avellini C, Crocè LS, Rosso N, Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA, Tell G, Tiribelli C. Mol Med. 2007 Jan-Feb;13(1-2):89-96. doi: 10.2119/2006-00084.dimaso.
    No content available to display!!!